Close
Nordic 9Nordic 9

Curie Capital (investor - Venture Capital)

Netherlands curiecapital.nl
See something wrong or missing? Let us know
Offices:Amsterdam

Curie Capital is a life science focused venture capital firm from the Netherlands

Average round investment:27.93M USD
Average number per year:1.7
Distribution: 2026 (1)2025 (4)2024 (2)2023 (1)2022 (1) See the entire list
Portfolio companies: Netherlands Laigo BioNetherlands TargED BiopharmaceuticalsNetherlands Avidicure See the entire list
Mostly invests in: Netherlands Netherlands (10) Health services (10)
See the entire list

Showing 3 of 10 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Curie Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Curie Capital

Name Criteria
Sweden Sound Bioventures
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.8
  • Active last 12 months: Yes
United States JJDC - Johnson & Johnson
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.9
  • Active last 12 months: Yes
Switzerland Pureos Bioventures
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 3.6
  • Active last 12 months: Yes
Germany Evonik Venture Capital GmbH
90%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Singapore Clay Capital
90%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Belgium Gimv
90%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
Luxembourg Vesalius Biocapital Partners
90%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Norway Hadean Ventures
90%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 3.1
  • Active last 12 months: Yes
Switzerland Novartis Venture Fund
89%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
Switzerland Wille Finance AG
89%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands
  • Average number of deals per year: 3.3
  • Active last 12 months: Yes
Top